A citation-based method for searching scientific literature

Richard M Bergenstal, Julio Rosenstock, Edward J Bastyr, Melvin J Prince, Yongming Qu, Scott J Jacober. Diabetes Care 2014
Times Cited: 24







List of co-cited articles
113 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
Julio Rosenstock, Richard M Bergenstal, Thomas C Blevins, Linda A Morrow, Melvin J Prince, Yongming Qu, Vikram P Sinha, Daniel C Howey, Scott J Jacober. Diabetes Care 2013
74
45

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
273
41

A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Richard M Bergenstal, Julio Rosenstock, Richard F Arakaki, Melvin J Prince, Yongming Qu, Vikram P Sinha, Daniel C Howey, Scott J Jacober. Diabetes Care 2012
86
37

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Vikram P Sinha, Siak Leng Choi, Danny Kwang Wei Soon, Kenneth F Mace, Kwee Poo Yeo, Shufen T H Lim, Daniel C Howey. J Clin Pharmacol 2014
30
33


Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Robert R Henry, Sunder Mudaliar, Theodore P Ciaraldi, Debra A Armstrong, Paivi Burke, Jeremy Pettus, Parag Garhyan, Siak Leng Choi, Scott J Jacober, Mary Pat Knadler,[...]. Diabetes Care 2014
46
33



Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism.
Mary Courtney Moore, Marta S Smith, Vikram P Sinha, John M Beals, M Dodson Michael, Scott J Jacober, Alan D Cherrington. Diabetes 2014
63
25

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
225
25

Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
David R Owens, Glenn Matfin, Louis Monnier. Diabetes Metab Res Rev 2014
52
25


Effects of PEG conjugation on insulin properties.
Kenneth D Hinds, Sung Wan Kim. Adv Drug Deliv Rev 2002
150
16



New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
181
16

The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.
Svend Havelund, Anne Plum, Ulla Ribel, Ib Jonassen, Aage Vølund, Jan Markussen, Peter Kurtzhals. Pharm Res 2004
268
16

PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.
T M Caparrotta, M Evans. Diabetes Obes Metab 2014
34
16

Role of continuous glucose monitoring for type 2 in diabetes management and research.
Robert Vigersky, Maneesh Shrivastav. J Diabetes Complications 2017
51
16

Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Roy W Beck, Tonya Riddlesworth, Katrina Ruedy, Andrew Ahmann, Richard Bergenstal, Stacie Haller, Craig Kollman, Davida Kruger, Janet B McGill, William Polonsky,[...]. JAMA 2017
451
16




Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette. JAMA 2006
12

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
238
12

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
239
12

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger. Diabetes 2004
409
12

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
R H A Becker, I Nowotny, L Teichert, K Bergmann, C Kapitza. Diabetes Obes Metab 2015
77
12





Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
236
12



Hepatoselectivity and the evolution of insulin.
R Herring, R H Jones, D L Russell-Jones. Diabetes Obes Metab 2014
48
12

The lente insulins.
K HALLAS-MOLLER. Diabetes 1956
48
12

CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY.
Vivian A Fonseca, George Grunberger, Henry Anhalt, Timothy S Bailey, Thomas Blevins, Satish K Garg, Yehuda Handelsman, Irl B Hirsch, Eric A Orzeck, Victor Lawrence Roberts,[...]. Endocr Pract 2016
106
12


Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
Marcus Lind, William Polonsky, Irl B Hirsch, Tim Heise, Jan Bolinder, Sofia Dahlqvist, Erik Schwarz, Arndís Finna Ólafsdóttir, Anders Frid, Hans Wedel,[...]. JAMA 2017
292
12

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.
Jens J Holst, John B Buse, Helena W Rodbard, Sultan Linjawi, Vincent C Woo, Trine Welløv Boesgaard, Kajsa Kvist, Stephen C Gough. J Diabetes Sci Technol 2015
14
21

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
H W Rodbard, B Cariou, B Zinman, Y Handelsman, A Philis-Tsimikas, T V Skjøth, A Rana, C Mathieu. Diabet Med 2013
64
8

Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes.
Katherine Esposito, Dario Giugliano. Expert Opin Biol Ther 2012
5
40


Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
225
8

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
8



Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo, Per Clauson, Søren C Tamer, Sungwoo Park. J Diabetes Investig 2013
75
8

Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes.
Concetta Irace, Raffaella Fiorentino, Claudio Carallo, Faustina Scavelli, Agostino Gnasso. Diabetes Technol Ther 2011
21
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.